Cargando…

Next generation Fc scaffold for multispecific antibodies

Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hind...

Descripción completa

Detalles Bibliográficos
Autores principales: Estes, Bram, Sudom, Athena, Gong, Danyang, Whittington, Douglas A., Li, Vivian, Mohr, Christopher, Li, Danqing, Riley, Timothy P., Shi, Stone D.-H., Zhang, Jun, Garces, Fernando, Wang, Zhulun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633962/
https://www.ncbi.nlm.nih.gov/pubmed/34877503
http://dx.doi.org/10.1016/j.isci.2021.103447
_version_ 1784608037127847936
author Estes, Bram
Sudom, Athena
Gong, Danyang
Whittington, Douglas A.
Li, Vivian
Mohr, Christopher
Li, Danqing
Riley, Timothy P.
Shi, Stone D.-H.
Zhang, Jun
Garces, Fernando
Wang, Zhulun
author_facet Estes, Bram
Sudom, Athena
Gong, Danyang
Whittington, Douglas A.
Li, Vivian
Mohr, Christopher
Li, Danqing
Riley, Timothy P.
Shi, Stone D.-H.
Zhang, Jun
Garces, Fernando
Wang, Zhulun
author_sort Estes, Bram
collection PubMed
description Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3′ interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies.
format Online
Article
Text
id pubmed-8633962
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86339622021-12-06 Next generation Fc scaffold for multispecific antibodies Estes, Bram Sudom, Athena Gong, Danyang Whittington, Douglas A. Li, Vivian Mohr, Christopher Li, Danqing Riley, Timothy P. Shi, Stone D.-H. Zhang, Jun Garces, Fernando Wang, Zhulun iScience Article Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3′ interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies. Elsevier 2021-11-15 /pmc/articles/PMC8633962/ /pubmed/34877503 http://dx.doi.org/10.1016/j.isci.2021.103447 Text en © 2021 The Authors. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Estes, Bram
Sudom, Athena
Gong, Danyang
Whittington, Douglas A.
Li, Vivian
Mohr, Christopher
Li, Danqing
Riley, Timothy P.
Shi, Stone D.-H.
Zhang, Jun
Garces, Fernando
Wang, Zhulun
Next generation Fc scaffold for multispecific antibodies
title Next generation Fc scaffold for multispecific antibodies
title_full Next generation Fc scaffold for multispecific antibodies
title_fullStr Next generation Fc scaffold for multispecific antibodies
title_full_unstemmed Next generation Fc scaffold for multispecific antibodies
title_short Next generation Fc scaffold for multispecific antibodies
title_sort next generation fc scaffold for multispecific antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633962/
https://www.ncbi.nlm.nih.gov/pubmed/34877503
http://dx.doi.org/10.1016/j.isci.2021.103447
work_keys_str_mv AT estesbram nextgenerationfcscaffoldformultispecificantibodies
AT sudomathena nextgenerationfcscaffoldformultispecificantibodies
AT gongdanyang nextgenerationfcscaffoldformultispecificantibodies
AT whittingtondouglasa nextgenerationfcscaffoldformultispecificantibodies
AT livivian nextgenerationfcscaffoldformultispecificantibodies
AT mohrchristopher nextgenerationfcscaffoldformultispecificantibodies
AT lidanqing nextgenerationfcscaffoldformultispecificantibodies
AT rileytimothyp nextgenerationfcscaffoldformultispecificantibodies
AT shistonedh nextgenerationfcscaffoldformultispecificantibodies
AT zhangjun nextgenerationfcscaffoldformultispecificantibodies
AT garcesfernando nextgenerationfcscaffoldformultispecificantibodies
AT wangzhulun nextgenerationfcscaffoldformultispecificantibodies